The FDA has approved Merck’s Enflonsia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants.
The approval is based on data from a phase 2b/3 trial, which showed a 60.5% reduction in RSV-associated medically attended lower respiratory infections compared to placebo, according to a June 9 news release from the drugmaker.
The treatment also reduced RSV-associated hospitalizations by 84.3%. Enflonsia is administered as a single 105 mg dose, regardless of infant weight, and is designed to provide protection through a typical five-month RSV season.
The CDC’s Advisory Committee on Immunization Practices is expected to review use recommendations later this month, with distribution expected to begin before the 2025-2026 RSV season.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
